REPORT HIGHLIGHTS

Current and Future Utilization Levels by Phase of Clinical Development

Sponsors’ Planned Budget Growth for Each Technology Over the Next 2–3 Years

Insights from Decision Makers at US, EU and ROW Biopharmaceutical Companies

Segmentation Analysis by Company Size and Geographic Region

Rationale for Premier Technology Provider Selection

Areas of Improvement for Clinical Trial Technology Providers

Perceptions of EDC, IVRS, IWRS, ePRO, CTMS and Clinical Trial Planning/Forecasting Tools

CLINICAL TRIAL TECHNOLOGY REPORT

2009 Clinical Trial Technology Utilization, Purchasing Preferences & Growth Outlook – WHAT´S HOT AND WHAT´S NOT

Utilization of clinical trial technologies across Phase 1–4 development is growing, but which technologies are expected to be the "winners" and "losers" over the next 2–3 years might surprise you. According to new research conducted by Life Science Strategy Group with nearly 110 clinical development decision makers at leading pharmaceutical and biotechnology companies in the US, Europe and Asia Pacific regions, utilization of clinical trial technologies, including EDC, IVRS, IWRS, ePRO, CTMS and clinical trial planning/forecasting tools is growing, and for some technologies, is expected to nearly double.

LSSG´s report takes an in–depth look at 6 of the leading clinical trial technologies to explore current and future utilization levels by phase of clinical development. In the report key decision makers comment on current and future technology utilization levels (as a percent of current trials utilizing the technology) for each of the six clinical trial technologies. In our analysis LSSG uncovers the technologies expected to see the greatest increases in utilization, further segmenting each technology by company size and geographic region.

The report goes on to further explore the top drivers of technology use, Sponsors´ preferences for purchasing clinical trial technology, and the type of vendor chosen. Not surprisingly, it is a critical time for clinical development, and factors (detailed in the study) extending beyond just "price" play a significant role in the ultimate choice of vendor for each technology. In the report, LSSG also explores Sponsors´ planned budget growth for each clinical trial technology over the next 2–3 years. Interestingly, even in this time of economic challenge, Sponsors at both large and small biopharmaceutical companies anticipate strong annual budget growth of up to 30% for select technologies.

You can learn about these and other key findings, gain in–depth insight into specific technology utilization trends, understand Sponsor purchasing preferences and anticipated budget growth for these technologies in LSSG´s Q2 2009 Clinical Trial Technology Utilization, Purchasing Preferences and Growth Outlook Report.

To download complimentary sample pages or to purchase the full comprehensive report, please visit:
www.lifesciencestrategy.com/publications.

---

Copyright © 2009. Life Science Strategy Group, LLC.